RC
ONCS

RegentAtlantic Capital’s OncoSec Medical Incorporated ONCS Stock Holding History

RegentAtlantic Capital’s Portfolio ONCS Stock Details ONCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$17K Hold
1,563
– – ﹤0.01% 663
2022
Q2 		$26K Hold
1,563
– – ﹤0.01% 670
2022
Q1 		$40K Hold
1,563
– – ﹤0.01% 681
2021
Q4 		$33K Hold
1,563
– – ﹤0.01% 682
2021
Q3 		$73K Buy
+1,563
New +$79.2K ﹤0.01% 649

Other funds holding ONCS

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RegentAtlantic Capital's ONCS Position: Q3 2022 in Review

RegentAtlantic Capital held its OncoSec Medical Incorporated (ONCS) position steady in Q3 2022 at 1,563 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #663.

RegentAtlantic Capital first reported a position in ONCS in Q3 2021 and has held it in 5 quarters since. The position peaked at $73K in Q3 2021. 23 funds tracked by Wall St. Rank hold ONCS as of Q3 2022.

  • RegentAtlantic Capital held 1,563 shares of OncoSec Medical Incorporated worth $17K as of Q3 2022.
  • RegentAtlantic Capital left its OncoSec Medical Incorporated share count unchanged in Q3 2022.
  • OncoSec Medical Incorporated made up ﹤0.01% of RegentAtlantic Capital's portfolio in Q3 2022, its #663 holding.
  • RegentAtlantic Capital first reported a position in OncoSec Medical Incorporated in Q3 2021 and has held it in 5 quarters since.
  • RegentAtlantic Capital's OncoSec Medical Incorporated position peaked at $73K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.